Study Comparing Favezelimab/Pembrolizumab with Chemotherapy for Hodgkin Lymphoma That Has Returned or Stopped Responding to Treatment

Inclusion Criteria

• Diagnosed with classical Hodgkin lymphoma (cHL) that shows up on certain scans.
• The cancer has returned after treatment or has not responded to the latest treatment, and all other known treatment options have been tried.
• The cancer has worsened after treatment with a specific type of drug called an anti-PD-(L)1 antibody, used alone or with other treatments.
• Able to provide a tumor sample from the last five years or a new sample that hasn't been treated with radiation.

Exclusion Criteria

• Have a condition that weakens the immune system or are taking medications that suppress the immune system.
• Have cancer that has spread to the brain or active involvement of the central nervous system.
• Have an active autoimmune disease needing treatment in the past two years, except for hormone replacement therapy.
• Have a history of lung inflammation that needed steroids or currently have lung disease.
• Have an active infection needing treatment.
• Have a history of a specific immune system disorder called hemophagocytic lymphohistiocytosis.
• Have uncontrolled seizures.
• Have serious heart disease.
• Have received cancer treatment or investigational drugs within four weeks before starting the study.
• Have had radiation therapy within two weeks before starting the study or have side effects from radiation needing steroids.
• Have not fully recovered from major surgery.
• Have another cancer that is getting worse or needed treatment in the past three years.
• Have a history of HIV.
• Have had a stem cell or organ transplant in the last five years.